Date(s) - April 14, 2021
7:00 pm EDT - 8:30 pm EDT
This on-line panel discussion will explore the role of clinical trials in fibrolamellar carcinoma treatment and the potential evolution of treatment strategies in the future. The event will feature oncologists from leading institutions, including Dana-Farber Cancer Institute, Johns Hopkins University, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Rush University. Specific topics to be covered will include:
- What are clinical trials and why are they so important?
- What trials are now open for fibrolamellar carcinoma?
- How does the Food and Drug Administration regulate clinical trials and review new therapeutics and combinations?
This panel discussion and audience Q&A session will be conducted as an interactive Zoom webinar and will begin at 7:00 pm Eastern time/4:00 pm Pacific time.
- Ghassan Abou-Alfa, MD
Memorial Sloan Kettering Cancer Center
- Ahmed Kaseb, MD, CMQ
Professor and Director, Hepatocellular Carcinoma Program
Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center
- Paul Kent, MD, FAAP
Associate Professor, Hematology and Oncology
Medical Director Fibrolamellar Carcinoma Program
Rush University Medical Center
- Allison O’Neill, MD
Director, Pediatric Liver Tumor Center of Excellence
Dana-Farber Cancer Institute
Boston Children’s Hospital
- Mark Yarchoan, MD
Assistant Professor of Oncology
Johns Hopkins University
Any fibrolamellar patients, caregivers and others interested in learning about clinical trials for FLC are invited. Medical and fibrolamellar research professionals are welcome as well.